Biosig Technologies Inc.

06/09/2025 | Press release | Distributed by Public on 06/09/2025 16:31

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Williams Mitchell Young
2. Date of Event Requiring Statement (Month/Day/Year)
05/28/2025
3. Issuer Name and Ticker or Trading Symbol
BioSig Technologies, Inc. [BSGM]
(Last) (First) (Middle)
C/O BIOSIG TECHNOLOGIES, INC., 12424 WILSHIRE BLVD., STE. 745
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Investment Officer
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
LOS ANGELES, CA 90025
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Restricted Common Stock 1,000,000(1) D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Exchangeable Shares(2) (2) (2) Common Stock 937,382(2) (2) D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Williams Mitchell Young
C/O BIOSIG TECHNOLOGIES, INC.
12424 WILSHIRE BLVD., STE. 745
LOS ANGELES, CA 90025
Chief Investment Officer

Signatures

/s/ Mitchell Young Williams 06/09/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Represents a restricted stock award of 1,000,000 shares of common stock, par value $0.001 per share (the "Common Stock") of BioSig Technologies, Inc. (the "Company") granted pursuant to the Company's 2023 Equity Incentive Plan. One-third of the shares (333,334 shares) will vest on the three-month anniversary of the grant date, subject to the reporting person's continued service with the Company through such date. The remaining two-thirds of the shares will vest in five subsequent quarterly installments-four equal installments of 133,333 shares each on each quarterly anniversary of the initial vesting date, and a final installment of 133,334 shares on the eighteen-month anniversary of the grant date-subject to continued service through each applicable vesting date.
(2) Represents the Common Stock that may be issued from time to time upon the exchange, retraction or redemption of exchangeable shares of BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (the "Exchangeable Shares"). Each Exchangeable Share may be exchanged for one share of Common Stock, subject to certain exceptions. The aggregate number of Exchangeable Shares that may be exchanged for Common Stock may not exceed 19.9% of the total outstanding Common Stock until such issuance is approved by the Company's stockholders. The Exchangeable Shares do not have an expiration date.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Biosig Technologies Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 09, 2025 at 22:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io